Back to Directory
Switch Biologics
Cambridge
Founded 2025
Engineered biologics with conditional activation for precision cancer immunotherapy
Switch Biologics is a UK biotechnology company developing engineered protein biologics for cancer immunotherapy.
The company applies directed evolution and protein engineering to build conditionally activated therapeutics that respond to two simultaneous molecular signals, a design intended to concentrate activity within tumours and reduce off-target toxicity.
Switch Biologics is in stealth mode and public information about its programmes and target indications remains limited.